Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
Here, we discuss the safety and management of adverse events associated with pembrolizumab plus axitinib combination therapy for metastatic renal cell carcinoma in patients on hemodialysis. A 76-year-old man was diagnosed with cT3aN0M0 renal cell carcinoma due to gross hematuria. Stereoscopic radiot...
Guardado en:
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Karger Publishers
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f836686a18da49219a96dc9f58f4a191 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:f836686a18da49219a96dc9f58f4a191 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:f836686a18da49219a96dc9f58f4a1912021-11-18T11:08:46ZCombination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report1662-657510.1159/000519855https://doaj.org/article/f836686a18da49219a96dc9f58f4a1912021-10-01T00:00:00Zhttps://www.karger.com/Article/FullText/519855https://doaj.org/toc/1662-6575Here, we discuss the safety and management of adverse events associated with pembrolizumab plus axitinib combination therapy for metastatic renal cell carcinoma in patients on hemodialysis. A 76-year-old man was diagnosed with cT3aN0M0 renal cell carcinoma due to gross hematuria. Stereoscopic radiotherapy for metastatic lesions of the ipsilateral kidney was performed 9 years after right laparoscopic radical nephrectomy. Soon after, the patient started to receive hemodialysis due to end-stage renal disease. Further stereoscopic radiotherapy was needed for metastasis of the ipsilateral kidney and lung. Fifteen years after diagnosis, systemic therapy was necessary to control new metastases, such as in the right scapular bone. We selected pembrolizumab plus axitinib combination therapy as the first-line systemic therapy for any risk as defined by the International Metastatic RCC Database Consortium. Although we needed to pay attention to the adverse events unique to hemodialysis, he underwent this combination therapy without any difficulty for 6 months. Here, we report the practice of combination therapy in patients on hemodialysis in light of the literature.Yuki KatsumataYoshihide KawasakiKayu TanakaDaisuke NakayamaHiromichi KatayamaShuichi ShimadaYohei SatakeTakuma SatoNaoki KawamoritaShinichi YamashitaTestuya SatoKosuke ShojiKoji MitsuzukaAkihiro ItoKarger Publishersarticleaxitinibhemodialysispembrolizumabrenal cell carcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1522-1529 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
axitinib hemodialysis pembrolizumab renal cell carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
axitinib hemodialysis pembrolizumab renal cell carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yuki Katsumata Yoshihide Kawasaki Kayu Tanaka Daisuke Nakayama Hiromichi Katayama Shuichi Shimada Yohei Satake Takuma Sato Naoki Kawamorita Shinichi Yamashita Testuya Sato Kosuke Shoji Koji Mitsuzuka Akihiro Ito Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report |
description |
Here, we discuss the safety and management of adverse events associated with pembrolizumab plus axitinib combination therapy for metastatic renal cell carcinoma in patients on hemodialysis. A 76-year-old man was diagnosed with cT3aN0M0 renal cell carcinoma due to gross hematuria. Stereoscopic radiotherapy for metastatic lesions of the ipsilateral kidney was performed 9 years after right laparoscopic radical nephrectomy. Soon after, the patient started to receive hemodialysis due to end-stage renal disease. Further stereoscopic radiotherapy was needed for metastasis of the ipsilateral kidney and lung. Fifteen years after diagnosis, systemic therapy was necessary to control new metastases, such as in the right scapular bone. We selected pembrolizumab plus axitinib combination therapy as the first-line systemic therapy for any risk as defined by the International Metastatic RCC Database Consortium. Although we needed to pay attention to the adverse events unique to hemodialysis, he underwent this combination therapy without any difficulty for 6 months. Here, we report the practice of combination therapy in patients on hemodialysis in light of the literature. |
format |
article |
author |
Yuki Katsumata Yoshihide Kawasaki Kayu Tanaka Daisuke Nakayama Hiromichi Katayama Shuichi Shimada Yohei Satake Takuma Sato Naoki Kawamorita Shinichi Yamashita Testuya Sato Kosuke Shoji Koji Mitsuzuka Akihiro Ito |
author_facet |
Yuki Katsumata Yoshihide Kawasaki Kayu Tanaka Daisuke Nakayama Hiromichi Katayama Shuichi Shimada Yohei Satake Takuma Sato Naoki Kawamorita Shinichi Yamashita Testuya Sato Kosuke Shoji Koji Mitsuzuka Akihiro Ito |
author_sort |
Yuki Katsumata |
title |
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report |
title_short |
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report |
title_full |
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report |
title_fullStr |
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report |
title_full_unstemmed |
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report |
title_sort |
combination therapy of pembrolizumab plus axitinib for a patient on hemodialysis with metastatic renal cell carcinoma: a case report |
publisher |
Karger Publishers |
publishDate |
2021 |
url |
https://doaj.org/article/f836686a18da49219a96dc9f58f4a191 |
work_keys_str_mv |
AT yukikatsumata combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT yoshihidekawasaki combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT kayutanaka combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT daisukenakayama combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT hiromichikatayama combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT shuichishimada combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT yoheisatake combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT takumasato combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT naokikawamorita combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT shinichiyamashita combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT testuyasato combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT kosukeshoji combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT kojimitsuzuka combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport AT akihiroito combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport |
_version_ |
1718420881703698432 |